Fasting Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's ciprofloxacin
extended-release 1000 mg tablets to Bayer's Cipro® XR 1000 mg tablets following a single,
oral 1000 mg (1 x 1000 mg) dose administered under fasting conditions.